Ensayos clínicos Solicite una Consulta en Mayo Clinic Centros, viajes y alojamientoInvestigación Feb. 25, 2020 Comparte en: FacebookTwitter Mostrar referencias National Marrow Donor Program. http://bethematch.org. Accessed Feb. 26, 2015. AskMayoExpert. Hematopoietic stem cell transplant. Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2015. AskMayoExpert. Graft-versus-host disease. Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2014. Barbara Woodward Lips Patient Education Center. Allogeneic blood and marrow transplant (BMT). Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2010. Riggin EA. Allscripts EPSi. Mayo Clinic, Rochester, Minn. July 20, 2016. Lee SJ, et al. 5 year results of bmt ctn 0201: Unrelated donor bone marrow is associated with better psychological well-being and less burdensome chronic gvhd symptoms than peripheral blood. American Society of Hematology. Meeting abstract. https://ash.confex.com/ash/2015/webprogram/Paper80881.html. Accessed July 19, 2016. Adams RH (expert opinion). Mayo Clinic, Rochester, Minn. Aug. 15, 2016. Geerdes PA (expert opinion). Mayo Clinic, Rochester, Minn. Aug. 17, 2012. Reunited and it feels pretty good. In the Loop. July 28, 2015. http://intheloop.mayoclinic.org. Accessed July 19, 2016. Singla A, et al. Incidence of supraventricular arrhythmias during autologous peripheral blood stem cell transplantation. Biology of Blood and Marrow Transplantation. 2013;19:1233. Hoffman R, et al. Overview of hematopoietic stem cell transplantation. In: Hematology: Basic Principles and Practice. 6th ed. Philadelphia, Pa.: Saunders Elsevier; 2013. http://www.clinicalkey.com. Accessed July 19, 2016. Dispenzieri A. POEMS syndrome: 2012 update on diagnosis, risk-stratification and management. American Journal of Hematology. 2012;87:804. Yang ZZ, et al. T-cell-mediated antitumor immunity in B-cell non-Hodgkin lymphoma: Activation, suppression and exhaustion. Leukemia and Lymphoma. 2015;56:2498. Diseases treatable by transplants. National Marrow Donor Program. https://bethematch.org/transplant-basics/how-transplants-work/diseases-treatable-by-transplants/. Accessed July 20, 2016. Majhail NS, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation. 2012;18:348. Yawn BP, et al. Management of sickle cell disease: Summary of the 2014 evidence-based report by expert panel members. JAMA. 2014;312:1033. NCCN member institutions. National Comprehensive Cancer Network. https://www.nccn.org. Accessed July 20, 2016. Cordes S, et al. Autologous stem cell transplantation in immunoglobulin light chain amyloidosis with factor X deficiency. Blood Coagulation and Fibrinolysis. 2016;27:101. Colborn LK. Office of Access Management. Mayo Clinic, Rochester, Minn. Jan. 28, 2016. Gertz MA, et al. Autologous stem cell transplant in 716 patients with multiple myeloma: Low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative. Mayo Clinic Proceedings. 2008;83:1131. O'Suoji C, et al. Rare pediatric non-Hodgkin lymphomas: A report from Children's Oncology Group Study ANHL 04B1. Pediatric Blood Cancer. 2016;63:794. Galardy PJ, et al. Targeting childhood, adolescent and young adult non-Hodgkin lymphoma: Therapeutic horizons. British Journal of Haematology. 2016;173:625. Slack JL, et al. Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: Outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch. Biology of Blood and Marrow Transplantation. 2013;19:1167. King AA, et al. Successful matched sibling donor marrow transplantation following reduced intensity conditioning in children with hemoglobinopathies. American Journal of Hematology. 2015;90:1093. Mayo Clinic to grow human cells in space: Testing stroke treatment. Mayo Clinic News Network. http://newsnetwork.mayoclinic.org. Accessed July 20, 2016. Muchtar E, et al. Autologous stem cell transplant for multiple myeloma patients 70 years or older. Bone Marrow Transplant. In press. Ansell SM. Targeting immune checkpoints in lymphoma. Current Opinion in Hematology. 2015;22:337. Hashmi S, et al. Survival aster mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: Systematic review and meta-analysis. The Lancet Haematology. 2016;1:e45-52. https://www.clinicalkey.com. Accessed July 20, 2016. A continuación se enumeran ensayos clínicos actuales.17 estudios en Programa de trasplante de médula ósea (estudios abiertos únicamente). Filtrar esta lista de estudios según la ubicación, el estado del estudio y más. A Study of Patients Treated for Chronic Granulomatous Disease Since 1995 Rochester, Minn. Chronic granulomatous disease (CGD) is an inherited immune system abnormality in which bone marrow transplantation has been shown to be curative. However the risks of transplantation are high and not all patients with CGD may need to undergo this high risk procedure. The purpose of this study is to determine the long term medical condition and daily functioning of patients with CGD after a transplant and if possible, compare these results to patients who do not undergo a transplant. Study of Iomab-B Prior to HCT vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory AML Rochester, Minn., Jacksonville, Fla. The primary objective of this study is to demonstrate the efficacy of Iomab-B, in conjunction with a Reduced Intensity Conditioning (RIC) regimen and protocol-specified allogeneic hematopoietic stem cell transplant (HCT), versus Conventional Care. A Study to Assess Feasibility and Benefit of a Patient-reported Outcomes Quality of Life Tool for Hematology and Medical Oncology Scottsdale/Phoenix, Ariz., Rochester, Minn. The purpose of this study is to determine the feasibility and benefit of a patient-reported outcomes quality of life tool for hematology and medical oncology. A Study to Compare Standard-Dose Combination Chemotherapy with High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Resistant Germ Cell Tumors Rochester, Minn. The purpose of this study is to compare standard-dose combination chemotherapy to high-dose combination chemotherapy and stem cell transplant in treating patients with germ cell tumors that have returned after a period of improvement or did not respond to treatment. Drugs used in chemotherapy, such as paclitaxel, ifosfamide, cisplatin, carboplatin, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before a stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them. Giving colony-stimulating factors, such as filgrastim or pegfilgrastim, and certain chemotherapy drugs, helps stem cells move from the bone marrow to the blood so they can be collected and stored. Chemotherapy is then given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. It is not yet known whether high-dose combination chemotherapy and stem cell transplant are more effective than standard-dose combination chemotherapy in treating patients with resistant or relapsed germ cell tumors. Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation Rochester, Minn. The purpose of this study is to evaluate the effectiveness of vedolizumab when added to background aGvHD prophylaxis regimen compared to placebo and background aGvHD prophylaxis regimen on intestinal aGvHD-free survival by Day +180 in participants who receive allo-HSCT as treatment for a hematologic malignancy or myeloproliferative disorder. Digital Stories and Psychosocial Wellbeing in Stem Cell Transplant Patients Scottsdale/Phoenix, Ariz. The proposed research will use a double-blind randomized controlled design to pilot test a model for how stories shared by a panel of HCT survivors impact the psychosocial well-being of the digital stories (DS) intervention condition of 55 patients who recently underwent HCT and their respective caregivers compared with 55 people in an information control (IC) condition and their caregivers (total 220 participants; N=110 per condition). Participants, recruited from the Mayo Clinic Arizona Cancer Center, will be randomly assigned to one of two conditions: the DS intervention or the IC video condition. Participants will questionnaires at baseline (T1), after the 4-week intervention (T2), and 3 months (100 days) later (T3). A Study to Evaluate Cancer Distress, Psychological Trauma, and Resiliency in Hospitalized Hematopoietic Stem Cell Transplant Patients Jacksonville, Fla. The purpose of this study is to better understand the distress experience of hospitalized patients undergoing hematopoietic stem cell transplant (HSCT), and to examine the relationship between cancer distress, psychological trauma, and resiliency over time. A Study to Evaluate Immune and Hematopoietic Cell Assessment in Clonal B Cell Conditions Rochester, Minn. The purpose of this study is to evaluate the immune and hematopoietic compartments in patients with monoclonal B cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL) in comparison to age-matched healthy control (HC) donors. Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Rochester, Minn. This randomized phase III trial studies ibrutinib to see how well it works compared to placebo when given before and after stem cell transplant in treating patients with diffuse large B-cell lymphoma that has returned after a period of improvement (relapsed) or does not respond to treatment (refractory). Before transplant, stem cells are taken from patients and stored. Patients then receive high doses of chemotherapy to kill cancer cells and make room for healthy cells. After treatment, the stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. Ibrutinib is a drug that may stop the growth of cancer cells by blocking a protein that is needed for cell growth. It is not yet known whether adding ibrutinib to chemotherapy before and after stem cell transplant may help the transplant work better in patients with relapsed or refractory diffuse large B-cell lymphoma. A Study to Evaluate Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant Scottsdale/Phoenix, Ariz. The purpose of this study is to provide ruxolitinib through an expanded access program for the treatment of graft-versus-host disease (GVHD) in United States to patients who are ineligible or unable to participate in any actively enrolling Incyte-sponsored clinical studies for ruxolitinib in the treatment of GVHD. Numeración de páginas Estudios clínicos Ir a página 11 Ir a página 22 SiguientePróxima página Mayo Clinic en Minnesota y Mayo Clinic en Phoenix/Scottsdale, Arizona han sido reconocidas entre los mejores hospitales oncológicos del país durante el período 2019-2020 por U.S. News and World Report. Lee más sobre este gran honor. Programa de trasplante de médula óseaPágina inicial del departamentoSeccionesSolicita una consultaDescripción generalAnálisis y procedimientosEnfermedades tratadasMédicosMédicos por sede y especialidadConocimientos y categoríasCentros, viajes y alojamientoEnsayos clínicosInvestigaciónExperiencias en Mayo Clinic y nuestros pacientes cuentan su historiaCostos y seguroNoticias de Mayo ClinicElegibilidadVolúmenes y resultadosRecursos para profesionales en MedicinaComunícate con nosotros Investigación: todo es por los pacientes SeccionesSolicita una consultaDescripción generalAnálisis y procedimientosEnfermedades tratadasMédicosMédicos por sede y especialidadConocimientos y categoríasCentros, viajes y alojamientoEnsayos clínicosInvestigaciónExperiencias en Mayo Clinic y nuestros pacientes cuentan su historiaCostos y seguroNoticias de Mayo ClinicElegibilidadVolúmenes y resultadosRecursos para profesionales en Medicina ORG-20193492 Departamentos y centros Departamentos y centros médicos Programa de trasplante de médula ósea